Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
3-Methylcrotonyl-CoA carboxylase (MCC) is a mitochondrial, biotin-dependent enzyme composed of two subunits (alpha and beta, encoded by MCCC1 and MCCC2 respectively) that catalyzes the carboxylation of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, a key step in the catabolic pathway of the essential amino acid leucine[1][3][4][5][7]. This reaction ultimately supports energy production by contributing to acetyl-CoA and acetoacetate pools. MCC deficiency is a well-characterized inborn error of metabolism leading to methylcrotonylglycinuria, and its diagnosis relies on detection of characteristic metabolites or reduced enzyme activity; the condition is often treatable with biotin supplementation due to the enzyme's strict requirement for biotin as a cofactor[4][6]. MCC belongs to the acyl-CoA carboxylase family, shares structural homology with propionyl-CoA carboxylase, and is widely conserved across mammals, plants, and bacteria[1][3][5][6][7].
Biotin supplementation: provides essential cofactor to restore or improve MCC activity in deficiency states No specific small-molecule inhibitors/activators of MCC in clinical use
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-Methylcrotonyl-CoA carboxylase (MCC).